Original
Evolución tras el intercambio a infliximab biosimilar en pacientes con enfermedad inflamatoria intestinal en remisión clínica
Evolution after switching to biosimilar infliximab in inflammatory bowel disease patients in clinical remission
Lourdes Guerrero Puentea, Eva Iglesias Floresa, José Manuel Beníteza,
, Rosario Medina Medinaa, Isabel Salgueiro Rodrígueza, Patricia Aguilar Meleroa, Manuel Jesús Cárdenas Aranzanab, Rafael González Fernándezc, Bárbara Manzanares Martinc, Valle García-Sáncheza
Autor para correspondencia
a Unidad de Gestión Clínica de Aparato Digestivo, Hospital Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Córdoba, España
b Unidad de Gestión Clínica de Farmacia, Hospital Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Córdoba, España
c Servicio de Inmunología, Hospital Reina Sofía, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba, Córdoba, España
Leído
6652
Vecesse ha leído el artículo
975
Total PDF
5677
Total HTML
| año/Mes | Html | Total | |
|---|---|---|---|
| 2025 12 | 21 | 10 | 31 |
| 2025 11 | 100 | 22 | 122 |
| 2025 10 | 82 | 11 | 93 |
| 2025 9 | 70 | 36 | 106 |
| 2025 8 | 68 | 13 | 81 |
| 2025 7 | 68 | 11 | 79 |
| 2025 6 | 67 | 4 | 71 |
| 2025 5 | 77 | 8 | 85 |
| 2025 4 | 97 | 3 | 100 |
| 2025 3 | 99 | 6 | 105 |
| 2025 2 | 157 | 4 | 161 |
| 2025 1 | 103 | 6 | 109 |
| 2024 12 | 85 | 4 | 89 |
| 2024 11 | 62 | 4 | 66 |
| 2024 10 | 90 | 5 | 95 |
| 2024 9 | 70 | 8 | 78 |
| 2024 8 | 62 | 6 | 68 |
| 2024 7 | 48 | 4 | 52 |
| 2024 6 | 68 | 6 | 74 |
| 2024 5 | 94 | 6 | 100 |
| 2024 4 | 72 | 5 | 77 |
| 2024 3 | 81 | 10 | 91 |
| 2024 2 | 74 | 2 | 76 |
| 2024 1 | 88 | 9 | 97 |
| 2023 12 | 72 | 11 | 83 |
| 2023 11 | 85 | 8 | 93 |
| 2023 10 | 87 | 9 | 96 |
| 2023 9 | 53 | 6 | 59 |
| 2023 8 | 50 | 3 | 53 |
| 2023 7 | 58 | 2 | 60 |
| 2023 6 | 84 | 4 | 88 |
| 2023 5 | 102 | 10 | 112 |
| 2023 4 | 71 | 5 | 76 |
| 2023 3 | 120 | 8 | 128 |
| 2023 2 | 88 | 12 | 100 |
| 2022 1 | 74 | 10 | 84 |
| 2022 12 | 68 | 26 | 94 |
| 2022 11 | 77 | 24 | 101 |
| 2022 10 | 71 | 25 | 96 |
| 2022 9 | 73 | 31 | 104 |
| 2022 8 | 76 | 22 | 98 |
| 2022 7 | 92 | 19 | 111 |
| 2022 6 | 72 | 25 | 97 |
| 2022 5 | 69 | 18 | 87 |
| 2022 4 | 76 | 27 | 103 |
| 2022 3 | 86 | 27 | 113 |
| 2022 2 | 78 | 18 | 96 |
| 2021 1 | 84 | 24 | 108 |
| 2021 12 | 61 | 11 | 72 |
| 2021 11 | 74 | 18 | 92 |
| 2021 10 | 90 | 18 | 108 |
| 2021 9 | 96 | 11 | 107 |
| 2021 8 | 67 | 16 | 83 |
| 2021 7 | 85 | 15 | 100 |
| 2021 6 | 110 | 32 | 142 |
| 2021 5 | 96 | 20 | 116 |
| 2021 4 | 197 | 19 | 216 |
| 2021 3 | 98 | 11 | 109 |
| 2021 2 | 72 | 10 | 82 |
| 2020 1 | 70 | 15 | 85 |
| 2020 12 | 77 | 12 | 89 |
| 2020 11 | 102 | 6 | 108 |
| 2020 10 | 56 | 6 | 62 |
| 2020 9 | 48 | 10 | 58 |
| 2020 8 | 37 | 17 | 54 |
| 2020 7 | 35 | 12 | 47 |
| 2020 6 | 31 | 11 | 42 |
| 2020 5 | 37 | 11 | 48 |
| 2020 4 | 30 | 10 | 40 |
| 2020 3 | 45 | 7 | 52 |
| 2020 2 | 58 | 5 | 63 |
| 2020 1 | 53 | 8 | 61 |
| 2019 12 | 39 | 11 | 50 |
| 2019 11 | 28 | 12 | 40 |
| 2019 10 | 1 | 2 | 3 |
| 2019 6 | 1 | 0 | 1 |
| 2019 3 | 0 | 2 | 2 |
| 2019 2 | 1 | 2 | 3 |
| 2018 11 | 2 | 2 | 4 |
| 2018 9 | 4 | 0 | 4 |
| 2018 8 | 1 | 0 | 1 |
| 2018 7 | 1 | 0 | 1 |
| 2018 5 | 1 | 1 | 2 |
| 2018 3 | 3 | 0 | 3 |
| 2018 2 | 3 | 0 | 3 |
| 2018 1 | 2 | 1 | 3 |
| 2017 12 | 6 | 3 | 9 |
| 2017 11 | 82 | 43 | 125 |
| 2017 10 | 8 | 6 | 14 |
| 2017 9 | 0 | 2 | 2 |
Mostrar todo
